Inozyme draws Buy at Jefferies on rare disease opportunity
https://seekingalpha.com/news/4139385-inozyme-stock-draws-buy-jefferies?source=feed_sector_healthcare
Aug 13, 2024 - Inozyme Pharma (INZY) stock gained after Jefferies assumed its coverage with a Buy rating and $17 price target, highlighting rare disease opportunities. Read more here.
0
Wave Life Sciences receives FDA rare disease designation for its duchenne muscular dystrophy treatment
https://seekingalpha.com/news/4138601-wave-life-sciences-receives-fda-rare-disease-designation-for-its-duchenne-muscular-dystrophy-treatment?source=feed_sector_healthcare
Aug 12, 2024 - Wave Life Sciences receives FDA Rare Pediatric Disease Designation for WVE-N531, a potential treatment for Duchenne muscular dystrophy.
0
Apellis: Rare Kidney Disease Data Leads To Possible First To Market
https://seekingalpha.com/article/4712636-apellis-rare-kidney-disease-data-leads-to-possible-first-to-market?source=feed_tag_editors_picks
Aug 09, 2024 - Positive results from phase 3 study of pegcetacoplan for C3G and IC-MPGN. Re-examination for approval in European markets. Find out why APLS stock is a Buy.
0
From vintage underwear to Olympics artifacts, take a rare tour of the Museum of Boulder’s collections warehouse
https://www.denverpost.com/2024/08/08/museum-of-boulder-collections-facility-tour/
Aug 08, 2024 - Guests have a rare opportunity to glimpse Boulder artifacts during a private tour of the Museum of Boulder’s Collections Facility, where out-of-commission museum objects go to rest when they’re not on display.
0
Rare Stock Picks In July 2024 - From 29 Discerning Analysts
https://seekingalpha.com/article/4710596-rare-stock-picks-in-july-2024-from-29-discerning-analysts?source=feed
Aug 06, 2024 - In our monthly Rare Stock Picks series, we're highlighting July 2024 investment picks. Click here for the list of July 2024 Buy recommendations.
0
Zevra wins FDA AdCom backing for rare disease therapy arimoclomol
https://seekingalpha.com/news/4133664-zevra-fda-adcom-backing-arimoclomol?source=feed_sector_healthcare
Aug 03, 2024 - Zevra Therapeutics (ZVRA) stock will be in focus as a group of FDA advisors backs its lead asset arimoclomol for Niemann-Pick disease type C. Read more here.
0
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4709975-ultragenyx-pharmaceutical-inc-rare-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 02, 2024 - Ultragenyx Pharmaceutical Inc. (NASDAQ:NASDAQ:RARE) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ETCompany ParticipantsJoshua Higa - Vice...
0
Agios' Pyrukynd misses primary endpoint in phase 3 pediatric rare blood disorder trial
https://seekingalpha.com/news/4133468-agios-pyrukynd-misses-primary-endpoint-phase-3-pediatric-rare-blood-disorder-trial?source=feed_sector_healthcare
Aug 02, 2024 - Agios Pharmaceuticals' Pyrukynd (mitapivat) did not meet primary endpoint in pediatric trial for PK deficiency. Read more here.
0
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
https://www.zacks.com/stock/news/2314816/compared-to-estimates-ultragenyx-rare-q2-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2314816
Aug 01, 2024 - Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2314646/ultragenyx-rare-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2314646
Aug 01, 2024 - Ultragenyx (RARE) delivered earnings and revenue surprises of 7.32% and 19.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0